154 related articles for article (PubMed ID: 11833786)
21. Association of CYP2C9 genotypes leading to high enzyme activity and colorectal cancer risk.
Martínez C; García-Martín E; Ladero JM; Sastre J; Garcia-Gamito F; Diaz-Rubio M; Agúndez JA
Carcinogenesis; 2001 Aug; 22(8):1323-6. PubMed ID: 11470765
[TBL] [Abstract][Full Text] [Related]
22. Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers.
Kirchheiner J; Kudlicz D; Meisel C; Bauer S; Meineke I; Roots I; Brockmöller J
Clin Pharmacol Ther; 2003 Aug; 74(2):186-94. PubMed ID: 12891229
[TBL] [Abstract][Full Text] [Related]
23. CYP2C9 polymorphism in non-steroidal anti-inflammatory drugs-induced gastropathy.
Ma J; Yang XY; Qiao L; Liang LQ; Chen MH
J Dig Dis; 2008 May; 9(2):79-83. PubMed ID: 18419640
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele.
Kidd RS; Straughn AB; Meyer MC; Blaisdell J; Goldstein JA; Dalton JT
Pharmacogenetics; 1999 Feb; 9(1):71-80. PubMed ID: 10208645
[TBL] [Abstract][Full Text] [Related]
25. Allelic and functional variability of cytochrome P4502C9.
Bhasker CR; Miners JO; Coulter S; Birkett DJ
Pharmacogenetics; 1997 Feb; 7(1):51-8. PubMed ID: 9110362
[TBL] [Abstract][Full Text] [Related]
26. Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes.
Takahashi H; Kashima T; Nomoto S; Iwade K; Tainaka H; Shimizu T; Nomizo Y; Muramoto N; Kimura S; Echizen H
Pharmacogenetics; 1998 Oct; 8(5):365-73. PubMed ID: 9825828
[TBL] [Abstract][Full Text] [Related]
27. Warfarin therapy in a patient homozygous for the CYP2C9 3 allele.
Ablin J; Cabili S; Lagziel A; Peretz H
Isr Med Assoc J; 2002 Feb; 4(2):139-41. PubMed ID: 11875991
[No Abstract] [Full Text] [Related]
28. The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement.
van der Weide J; Steijns LS; van Weelden MJ; de Haan K
Pharmacogenetics; 2001 Jun; 11(4):287-91. PubMed ID: 11434505
[TBL] [Abstract][Full Text] [Related]
29. Allelic variants of cytochrome P450 2C9 modify the interaction between nonsteroidal anti-inflammatory drugs and coumarin anticoagulants.
Visser LE; van Schaik RH; van Vliet M; Trienekens PH; De Smet PA; Vulto AG; Hofman A; van Duijn CM; Stricker BH
Clin Pharmacol Ther; 2005 Jun; 77(6):479-85. PubMed ID: 15961979
[TBL] [Abstract][Full Text] [Related]
30. CYP2C9 polymorphisms in human tumors.
Knüpfer H; Stanitz D; Preiss R
Anticancer Res; 2006; 26(1A):299-305. PubMed ID: 16475710
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of cytochrome P4502C9 metabolic activity with tolbutamide in CYP2C91 heterozygotes.
Lee CR; Pieper JA; Hinderliter AL; Blaisdell JA; Goldstein JA
Clin Pharmacol Ther; 2002 Nov; 72(5):562-71. PubMed ID: 12426520
[TBL] [Abstract][Full Text] [Related]
32. Frequency of CYP2C9 polymorphisms affecting warfarin metabolism in a large anticoagulant clinic cohort.
Moridani M; Fu L; Selby R; Yun F; Sukovic T; Wong B; Cole DE
Clin Biochem; 2006 Jun; 39(6):606-12. PubMed ID: 16630605
[TBL] [Abstract][Full Text] [Related]
33. Influence of cytochrome P450 CYP2C9 genotypes in lung cancer risk.
García-Martín E; Martínez C; Ladero JM; Gamito FJ; Rodriguez-Lescure A; Agúndez JA
Cancer Lett; 2002 Jun; 180(1):41-6. PubMed ID: 11911968
[TBL] [Abstract][Full Text] [Related]
34. Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes.
Yamazaki H; Inoue K; Chiba K; Ozawa N; Kawai T; Suzuki Y; Goldstein JA; Guengerich FP; Shimada T
Biochem Pharmacol; 1998 Jul; 56(2):243-51. PubMed ID: 9698079
[TBL] [Abstract][Full Text] [Related]
35. Interethnic differences of CYP2C9 alleles in healthy Hungarian and Roma population samples: relationship to worldwide allelic frequencies.
Sipeky C; Lakner L; Szabo M; Takacs I; Tamasi V; Polgar N; Falus A; Melegh B
Blood Cells Mol Dis; 2009; 43(3):239-42. PubMed ID: 19541511
[TBL] [Abstract][Full Text] [Related]
36. Acenocoumarol pharmacokinetics in relation to cytochrome P450 2C9 genotype.
Thijssen HH; Ritzen B
Clin Pharmacol Ther; 2003 Jul; 74(1):61-8. PubMed ID: 12844136
[TBL] [Abstract][Full Text] [Related]
37. High frequency of mutations related to impaired CYP2C9 metabolism in a Caucasian population.
García-Martín E; Martínez C; Ladero JM; Gamito FJ; Agúndez JA
Eur J Clin Pharmacol; 2001 Apr; 57(1):47-9. PubMed ID: 11372590
[TBL] [Abstract][Full Text] [Related]
38. Genetic regulation of warfarin metabolism and response.
Daly AK; Aithal GP
Semin Vasc Med; 2003 Aug; 3(3):231-8. PubMed ID: 15199455
[TBL] [Abstract][Full Text] [Related]
39. Effect of CYP2C polymorphisms on the pharmacokinetics of phenytoin in Japanese patients with epilepsy.
Hashimoto Y; Otsuki Y; Odani A; Takano M; Hattori H; Furusho K; Iui K
Biol Pharm Bull; 1996 Aug; 19(8):1103-5. PubMed ID: 8874828
[TBL] [Abstract][Full Text] [Related]
40. The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels.
Kerb R; Aynacioglu AS; Brockmöller J; Schlagenhaufer R; Bauer S; Szekeres T; Hamwi A; Fritzer-Szekeres M; Baumgartner C; Ongen HZ; Güzelbey P; Roots I; Brinkmann U
Pharmacogenomics J; 2001; 1(3):204-10. PubMed ID: 11908757
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
